bioAffinity Technologies, Inc.

Based in San Antonio, Texas, bioAffinity Technologies, Inc. has focused on revolutionary cancer diagnostics since its incorporation in 2014. The company develops non-invasive laboratory tests specifically designed to detect early-stage lung cancer and other respiratory diseases. By prioritizing patient comfort and accessibility, the firm provides a critical alternative to more invasive traditional screening methods.

The company’s flagship product, CyPath Lung, utilizes advanced flow cytometry and automated analysis to identify cancer at its earliest stages. This test specifically analyzes a patient’s sputum, or phlegm, to find unique cell populations shed from lung tumors. Furthermore, the system detects specific characteristics indicative of cancer-related cells, which allows for a highly accurate diagnosis before the disease progresses.

To manage these innovations, bioAffinity operates through two distinct segments: Diagnostic Research and Development and Laboratory Services. These divisions work in tandem to refine diagnostic accuracy and provide reliable testing results to the medical community across the United States. Ultimately, bioAffinity aims to transform the standard of lung care by making early detection a routine part of respiratory health management.